S&P 500   5,117.95 (+0.43%)
DOW   39,014.20 (+0.05%)
QQQ   442.92 (+0.89%)
AAPL   178.10 (-1.47%)
MSFT   412.56 (-0.26%)
META   498.64 (+1.74%)
GOOGL   137.77 (-0.50%)
AMZN   177.88 (+0.63%)
TSLA   200.82 (-0.53%)
NVDA   818.50 (+3.46%)
NIO   5.83 (+1.39%)
AMD   199.56 (+3.65%)
BABA   74.89 (+1.16%)
T   16.95 (+0.12%)
F   12.45 (+0.08%)
MU   95.47 (+5.36%)
CGC   3.27 (-0.61%)
GE   158.44 (+0.99%)
DIS   111.34 (-0.22%)
AMC   4.40 (+1.85%)
PFE   26.58 (+0.08%)
PYPL   60.62 (+0.46%)
XOM   106.14 (+1.55%)
S&P 500   5,117.95 (+0.43%)
DOW   39,014.20 (+0.05%)
QQQ   442.92 (+0.89%)
AAPL   178.10 (-1.47%)
MSFT   412.56 (-0.26%)
META   498.64 (+1.74%)
GOOGL   137.77 (-0.50%)
AMZN   177.88 (+0.63%)
TSLA   200.82 (-0.53%)
NVDA   818.50 (+3.46%)
NIO   5.83 (+1.39%)
AMD   199.56 (+3.65%)
BABA   74.89 (+1.16%)
T   16.95 (+0.12%)
F   12.45 (+0.08%)
MU   95.47 (+5.36%)
CGC   3.27 (-0.61%)
GE   158.44 (+0.99%)
DIS   111.34 (-0.22%)
AMC   4.40 (+1.85%)
PFE   26.58 (+0.08%)
PYPL   60.62 (+0.46%)
XOM   106.14 (+1.55%)
S&P 500   5,117.95 (+0.43%)
DOW   39,014.20 (+0.05%)
QQQ   442.92 (+0.89%)
AAPL   178.10 (-1.47%)
MSFT   412.56 (-0.26%)
META   498.64 (+1.74%)
GOOGL   137.77 (-0.50%)
AMZN   177.88 (+0.63%)
TSLA   200.82 (-0.53%)
NVDA   818.50 (+3.46%)
NIO   5.83 (+1.39%)
AMD   199.56 (+3.65%)
BABA   74.89 (+1.16%)
T   16.95 (+0.12%)
F   12.45 (+0.08%)
MU   95.47 (+5.36%)
CGC   3.27 (-0.61%)
GE   158.44 (+0.99%)
DIS   111.34 (-0.22%)
AMC   4.40 (+1.85%)
PFE   26.58 (+0.08%)
PYPL   60.62 (+0.46%)
XOM   106.14 (+1.55%)
S&P 500   5,117.95 (+0.43%)
DOW   39,014.20 (+0.05%)
QQQ   442.92 (+0.89%)
AAPL   178.10 (-1.47%)
MSFT   412.56 (-0.26%)
META   498.64 (+1.74%)
GOOGL   137.77 (-0.50%)
AMZN   177.88 (+0.63%)
TSLA   200.82 (-0.53%)
NVDA   818.50 (+3.46%)
NIO   5.83 (+1.39%)
AMD   199.56 (+3.65%)
BABA   74.89 (+1.16%)
T   16.95 (+0.12%)
F   12.45 (+0.08%)
MU   95.47 (+5.36%)
CGC   3.27 (-0.61%)
GE   158.44 (+0.99%)
DIS   111.34 (-0.22%)
AMC   4.40 (+1.85%)
PFE   26.58 (+0.08%)
PYPL   60.62 (+0.46%)
XOM   106.14 (+1.55%)
NASDAQ:AGIO

Agios Pharmaceuticals (AGIO) Stock Price, News & Analysis

$32.95
+0.63 (+1.95%)
(As of 11:33 AM ET)
Today's Range
$32.24
$33.04
50-Day Range
$21.32
$34.81
52-Week Range
$19.80
$35.50
Volume
183,367 shs
Average Volume
920,167 shs
Market Capitalization
$1.85 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$33.50

Agios Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
3.7% Upside
$33.50 Price Target
Short Interest
Bearish
13.97% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.91
Upright™ Environmental Score
News Sentiment
-0.08mentions of Agios Pharmaceuticals in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$1.07 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($5.25) to ($5.81) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.07 out of 5 stars

Medical Sector

805th out of 957 stocks

Pharmaceutical Preparations Industry

370th out of 440 stocks


AGIO stock logo

About Agios Pharmaceuticals Stock (NASDAQ:AGIO)

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism. The company develops PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias; and AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

AGIO Stock Price History

AGIO Stock News Headlines

Agios Pharmaceuticals Inc AGIO
Agios Pharmaceuticals (NASDAQ:AGIO) PT Lowered to $30.00
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Revolutionary Device Redefines Cancer Detection
Discover the breakthrough device that could transform the lives of the estimated 68 million Americans affected by skin cancer. Achieving unprecedented accuracy, this device identifies cancer's molecular signature in just 1.5 seconds. This innovation marks a rapid advance in the battle against cancer. See how investors are unlocking 10% in bonus shares for a limited time.
Q4 2023 Agios Pharmaceuticals Inc Earnings Call
Earnings Preview: Agios Pharmaceuticals
See More Headlines
Receive AGIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agios Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/15/2024
Today
3/01/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AGIO
Fax
N/A
Employees
389
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$33.50
High Stock Price Target
$42.00
Low Stock Price Target
$28.00
Potential Upside/Downside
+3.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-352,090,000.00
Net Margins
-1,312.64%
Pretax Margin
-1,312.64%

Debt

Sales & Book Value

Annual Sales
$26.82 million
Book Value
$14.43 per share

Miscellaneous

Free Float
53,812,000
Market Cap
$1.82 billion
Optionable
Optionable
Beta
0.76
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Brian M. Goff M.B.A. (Age 55)
    CEO & Director
    Comp: $1.23M
  • Ms. Cecilia Jones (Age 49)
    Chief Financial Officer
    Comp: $403.36k
  • Mr. James William Burns (Age 46)
    Corporate Secretary & Chief Legal Officer
    Comp: $660.33k
  • Dr. Sarah Gheuens M.D. (Age 44)
    Ph.D., Chief Medical Officer and Head of Research & Development
    Comp: $769.2k
  • Dr. Lewis Clayton Cantley Ph.D. (Age 75)
    Co-Founder & Member of Scientific Advisory Board
    Comp: $50k
  • Dr. Tak Wah Mak D.Sc. (Age 78)
    FRSC, Ph.D., Co-Founder & Member of Scientific Advisory Board
  • Dr. Craig B. Thompson M.D. (Age 71)
    Co-Founder & Chairman of Scientific Advisory Board
  • Dr. Shin-San Su Ph.D. (Age 68)
    Co-Founder & Member of Scientific Advisory Board
  • Mr. T. J. Washburn Jr. (Age 43)
    Principal Accounting Officer
  • Dr. Clive Patience Ph.D. (Age 60)
    Chief Technical Operations Officer














AGIO Stock Analysis - Frequently Asked Questions

Should I buy or sell Agios Pharmaceuticals stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AGIO shares.
View AGIO analyst ratings
or view top-rated stocks.

What is Agios Pharmaceuticals' stock price target for 2024?

4 analysts have issued 12 month target prices for Agios Pharmaceuticals' shares. Their AGIO share price targets range from $28.00 to $42.00. On average, they expect the company's stock price to reach $33.50 in the next twelve months. This suggests a possible upside of 3.7% from the stock's current price.
View analysts price targets for AGIO
or view top-rated stocks among Wall Street analysts.

How have AGIO shares performed in 2024?

Agios Pharmaceuticals' stock was trading at $22.27 at the start of the year. Since then, AGIO stock has increased by 45.1% and is now trading at $32.32.
View the best growth stocks for 2024 here
.

When is Agios Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our AGIO earnings forecast
.

How were Agios Pharmaceuticals' earnings last quarter?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) issued its quarterly earnings results on Thursday, February, 15th. The biopharmaceutical company reported ($1.72) EPS for the quarter, missing the consensus estimate of ($1.64) by $0.08. The biopharmaceutical company had revenue of $7.10 million for the quarter, compared to analyst estimates of $7.80 million. Agios Pharmaceuticals had a negative net margin of 1,312.64% and a negative trailing twelve-month return on equity of 38.08%. The firm's revenue was up 65.1% compared to the same quarter last year. During the same period in the prior year, the company earned $0.67 EPS.

What ETFs hold Agios Pharmaceuticals' stock?
What is Jackie Fouse's approval rating as Agios Pharmaceuticals' CEO?

11 employees have rated Agios Pharmaceuticals Chief Executive Officer Jackie Fouse on Glassdoor.com. Jackie Fouse has an approval rating of 100% among the company's employees. This puts Jackie Fouse in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Agios Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), bluebird bio (BLUE), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), Tesla (TSLA) and Netflix (NFLX).

Who are Agios Pharmaceuticals' major shareholders?

Agios Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.89%), Bellevue Group AG (7.18%), Armistice Capital LLC (6.31%), Dimensional Fund Advisors LP (4.65%), First Trust Advisors LP (3.25%) and Price T Rowe Associates Inc. MD (2.91%). Insiders that own company stock include Brian Goff, Carman Alenson, Cecilia Jones, Christopher Bowden, Darrin Miles, David P Schenkein, Jacqualyn A Fouse, James William Burns, Kaye I Foster-Cheek, Sarah Gheuens, Theodore James Jr Washburn and Tsveta Milanova.
View institutional ownership trends
.

How do I buy shares of Agios Pharmaceuticals?

Shares of AGIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AGIO) was last updated on 3/1/2024 by MarketBeat.com Staff